PRIME-ROSE builds on a bottom-up, investigator-initiated family of clinical trials in precision cancer medicine, which have successfully brought up inclusion rates to offer additional lines of treatment and provide patient benefit. At the kick-off in Oslo September 18-20, PRIME-ROSE partners and key stakeholders met to go through the work plan and accelerate the start-up of the project tasks.
PRIME-ROSE Coordinator Kjetil Taskén says: “Most importantly, PRIME-ROSE will allow us to search around Europe to find patients with rare combinations of cancer disease, biomarker, and treatment in parallel ongoing trials to build the evidence of what treatments are working for patients. This is a “triple-win” – for patients, investigators and industry partners – as we will build the knowledge base faster and more effectively”.
Complete original news article from the PRIME-ROSE homepage, with photo gallery:
Official Opening of the Horizon EU Cancer Mission PRIME-ROSE project
Previous new article about PRIME-ROSE from ous-research.no:
PRIME-ROSE: EU project receives 6 million EUR from EU Cancer Mission